Healthcare ratings roundup - new coverage

• Theravance Biopharma (NASDAQ:TBPH) initiated with Overweight rating and $42 (71% upside) price target by Piper Jaffray.
• Viveve Medial (NASDAQ:VIVE) initiated with Buy rating and $8 (59% upside) price target by B. Riley.
• Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $164 (29% upside) price target by Deutsche Bank.
• Halozyme Therapeutics (NASDAQ:HALO) initiated with Buy rating and $12 (42% upside) price target by Deutsche Bank.
• Cynosure (NASDAQ:CYNO) initiated with Buy rating and $60 (47% upside) price target by Aegis Capital.
• ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Hold rating and $9.50 (10% upside) price target by Deutsche Bank.
• Aurinia Pharmaceuticals (NASDAQ:AUPH) initiated with Speculative Buy rating and $8 (214% upside) price target by Mackie Research Capital.
• Achaogen (NASDAQ:AKAO) initiated with Buy rating and $10 (166% upside) price target by Aegis Capital.
• Kindred Biosciences (NASDAQ:KIN) initiated with Buy rating and $7.50 (46% upside) price target by Ladenburg Thalmann.
• Global Blood Therapeutics (NASDAQ:GBT) initiated with Buy rating and $47 (210% upside) price target by Roth Capital.
• Obalon Therapeutics (NASDAQ:OBLN) initiated with Buy rating and $28 (207% upside) price target by Canaccord Genuity. Initiated with Buy rating and $18 (97% upside) price target by Stifel Nicolaus.